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Background. Immune activation has been implicated in the excess mortality in human immunodeﬁciency virus (HIV)-infected
patients, due to cardiovascular diseases and malignancies. Statins may modulate this immune activation. We assessed the capacity of
rosuvastatin to mitigate immune activation in treatment-naive HIV-infected patients.
Methods. In a randomized double-blind placebo-controlled crossover study, we explored the effects of 8 weeks of rosuvastatin
20 mg in treatment-naive male HIV-infected patients (n = 28) on immune activation markers: neopterin, soluble Toll-like receptor
(TLR)2, sTLR4, interleukin (IL)-6, IL-1Ra, IL-18, D-dimer, highly sensitive C-reactive protein, and CD38 and/or human leukocyte
antigen-DR expression on T cells. Baseline data were compared with healthy male controls (n = 10). Furthermore, the effects
of rosuvastatin on HIV-1 RNA, CD4/CD8 T-cell count, and low-density lipoprotein cholesterol were examined and side effects
were registered.
Results. T-cell activation levels were higher in patients than in controls. Patients had higher levels of circulating IL-18, sTLR2,
and neopterin (all P < .01). Twenty patients completed the study. Rosuvastatin increased the CD4/CD8 T-cell ratio (P = .02). No
effect on other markers was found.
Conclusions. Patients infected with HIV had higher levels of circulating neopterin, IL-18, sTLR2, and T-cell activation markers.
Rosuvastatin had a small but signiﬁcant positive effect on CD4/CD8 T-cell ratio, but no inﬂuence on other markers of T-cell
activation and innate immunity was identiﬁed (The Netherlands National Trial Register [NTR] NTR 2349, http://www.
trialregister.nl/trialreg/index.asp).
Keywords. HIV-1; 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors; immune activation; statin.
Despite the enormous success of highly active antiretroviral
therapy (ART), life expectancy of patients infected with
human immunodeﬁciency virus (HIV) still lags behind the ge-
neral population [1–3]. In the current treatment era, excess
mortality is, to a large extent, due to non-acquired immune de-
ﬁciency syndrome (AIDS)-deﬁning diseases, such as malignan-
cies and cardiovascular diseases. Several factors may be held
responsible: for example, increased prevalence of smoking
in HIV-patients, toxicity of ART, and socioeconomic factors
[4, 5]. Moreover, several studies have suggested that persistent
immune activation and coagulation may play an important
role in the pathogenesis of these complications [6, 7].
In patients infected with HIV, elevated plasma levels of lipo-
polysaccharide (LPS), neopterin (a soluble marker for activation
of monocytes), and of several proinﬂammatory and anti-
inﬂammatory cytokines such as interleukin (IL)-6 and IL-10
have been reported [6, 8]. In addition, increased concentrations
of IL-6 and D-dimer have been found to correlate with mortality
in patients infected with HIV [9].
It has been postulated that modulating this inﬂammation and
immune activation may counter the increased risk of non-
AIDS-deﬁning diseases [6]. Two recent studies stated that the
use of statins reduces all-cause mortality in patients infected
with HIV [10, 11]. Statins, or 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors, are lipid-lowering agents. There is
an ongoing debate on the possible pleiotropic effects of statins.
Hodgkinson et al [12] reported that statins have an inhibitory
effect on the LPS/Toll-like receptor (TLR)4 inﬂammatory re-
sponse. In the JUPITER study, the use of rosuvastatin resulted
in a signiﬁcant decrease in highly sensitive C-reactive protein
(hsCRP) levels and reduced the number of vascular events in
patients with elevated hsCRP, indicating an anti-inﬂammatory
effect [13]. Several studies have investigated the effects of sta-
tins in patients infected with HIV. Ganesan et al [14] reported
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a reduction of T-cell activation levels after 8 weeks of ator-
vastatin. Others demonstrated a similar decline in T-cell acti-
vation after 48 weeks of rosuvastatin in patients treated with
ART [15].
In this study, we explored the baseline differences in soluble
markers of immune activation and in T-cell activation status be-
tween HIV-infected subjects and controls, and we investigated
the effects of rosuvastatin on these markers in HIV-infected
subjects in a double-blind placebo-controlled crossover trial.
Only ART-naive patients were selected, to exclude the effect
of treatment. We postulated that the use of rosuvastatin decreas-
es the concentrations of soluble markers of innate immunity
with resulting modulation of T-cell activation. We chose to ex-
amine the effect of rosuvastatin, because this statin has been in-
vestigated in the JUPITER study [13] and is proven to be well
tolerated in patients infected with HIV [16, 17].
METHODS
Study Population
We included ART-naive HIV-infected male patients from April
2011 until January 2013 in the Onze Lieve Vrouwe Gasthuis
(OLVG) Hospital in Amsterdam. Male volunteers, conﬁrmed
HIV-negative, who underwent a wisdom tooth extraction for
noninﬂammatory reasons more than 2 weeks before inclusion,
were included as healthy controls. The inclusion criteria for
HIV-patients were an age of 18 years or older, having CD4
cell counts on 2 occasions higher than 350 cells/mm³ and
HIV-1 RNA higher than 1000 copies/mL. Patients were eligible
if there was no evidence of acute HIV-infection, which was de-
ﬁned as the presence of a detectable HIV-1 viral RNA in the
presence of a nonreactive HIV-1 or HIV-2 antibody assay or
an indeterminate Western blot. Laboratory results at screening
were aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) ≤1.5 times the upper limit of normal
(ULN), creatine kinase ≤3 times the ULN, absolute neutrophil
count ≥1000/mm3, hemoglobin ≥7.5 mmol/L, platelet count
≥100 000/mm3, creatinine ≤2 times the ULN, amylase and li-
pase ≤1.25 times the ULN, and low-density lipoprotein (LDL)
≥1.0 mmol/L.
Exclusion criteria were active drug use or alcohol depen-
dence, serious illness, including opportunistic infections or neo-
plasm, requiring systemic treatment and/or hospitalization 30
days before entry of the study.
To ensure rosuvastatin was well tolerated, participants were
excluded if there was known hypersensitivity to this drug or
its components, a history of myositis or rhabdomyolysis, the
use of drugs that signiﬁcantly interact with rosuvastatin, or
the use of other lipid-lowering agents. To assure there was no
confounding on the immune response, use of concurrent im-
mune modulators or vaccinations within 6 weeks of study
entry were exclusion criteria as well. All participants provided
written informed consent.
Study Design
We completed a double-blind randomized placebo-controlled
pilot study with a crossover design. The HIV-infected partici-
pants were assigned to 2 random groups: 1 received rosuvastatin
20 mg qd, and the other received placebo during 8 weeks. After
this ﬁrst cycle, both study groups discontinued all study-related
medications for 4 weeks, referred to as the washout period.
Next, subjects receiving placebo switched to rosuvastatin and
vice versa for a period of 8 more weeks. Throughout the
study, participants had scheduled visits at the clinic every 4
weeks. Blood was drawn at 4 weeks (screening) and 1 day (base-
line) before start of medication and on week 4, 8, 12, 16, and 20
after the start of medication. Noninfected controls donated
blood samples once for all the parameters.
The carryover effect is deﬁned as the persistence of effect of a
treatment applied in one period, in a subsequent period. To
minimize this effect, a washout period of 4 times the action du-
ration of a treatment has been recommended [18]. Because the
half-life of rosuvastatin is 19 hours, we estimated a washout
period of 4 weeks to be sufﬁcient.
To ensure the double-blind character of the study, the treat-
ing physician was not informed on the results of blood tests
during the study period, and the samples for the lipid panel
were measured after completion of the study.
Because both immune activation and statin use may cause fa-
tigue, a questionnaire estimating quality of life was ﬁlled out at
baseline, week 8, and week 20. This contained the Medical Out-
comes Study HIV Health Survey (MOS-HIV) questionnaire
and a combined complaints list, which was derived from the Eu-
ropean Organization for Research and Treatment of Cancer
Quality of Life Questionnaire-Core 30 and has been used in
HIV-infected patients and statin users [19, 20].
Laboratory Methods
Blood was drawn in the morning, after the appliance of a light
tourniquet, into vacutainer tubes using a 21-gauge butterﬂy
needle (BD Safety Lok Blood Collection Set, Plymouth, UK).
On the same day, in the Haematology and Clinical Chemistry
Laboratory of the OLVG Hospital, CD3+, CD4+, and CD8+
counts and expression of the T-cell activation markers were
measured using anti-CD8 ﬂuorescein isothiocyanate (SK1, im-
munoglobulin [Ig]G1), anti-CD38 phycoerythrin (HB7, IgG1),
anti-CD3 peridinin chlorophyll (SK7, IgG1), and anti-human
leukocyte antigen (HLA)-DR allophycocyanin (L243, IgG2a)
from BD′s MultiTest reagent kit on blood collected in tubes
containing 7.2 mg of K2- ethylenediaminetetraacetic acid
(EDTA) (BD, Plymouth, UK). Twenty microliters of monoclo-
nal antibody mixture was added to a TruCOUNT FACS tube
(BD) and mixed with 50 μL of EDTA whole blood. After an in-
cubation period of 15 minutes, 1 mL lysing solution (BD) was
added to lyse all erythrocytes. After another incubation period
of 30 minutes, the samples were run on a FACS Calibur (BD).
Gating was performed using CellQuestpro software (BD).
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T-helper cells were deﬁned as CD3+CD8− cells, and cytotoxic T
cells were deﬁned as CD3+CD8+. Quadrants were set on distinct
CD38 and HLA-DR-negative subpopulations.
The Microbiology Laboratory of the OLVG hospital used
the COBAS AmpliPrep/COBAS TaqMan HIV-1 test, version
2.0 (Roche Molecular Systems, Pleasanton, CA) for the quanti-
ﬁcation of HIV type-1 RNA in plasma with a quantitative range
of 20–10 000 000 copies/mL.
The Laboratory of Experimental Internal Medicine of
the Radboud University Medical Centre measured soluble
TLR (sTLR)2 and sTLR4 by commercial enzyme-linked
immunosorbent assay (ELISA) kits (USCN Life Science, Inc.,
Wuhan, China) with a lower limit of detection of 0.62 ng/mL
and 1.3 ng/mL, respectively. Circulating IL-1Ra, IL-6, and
IL-18 were measured using Luminex assays (Merck Millipore,
Billerica, MA) with a lower detection limit of 9.8 pg/mL,
2.4 pg/mL, and 9.8 pg/mL, respectively. Competitive ELISA
(IBL International, Hamburg, Germany) was used for the
quantitative determination of neopterin and had a lower limit
of detection of 1.35 nmol/L.
Statistical Analysis
Ganesan et al [14], studying 22 patients receiving atorvastatin
80 mg qd, found signiﬁcant decreases in the proportion of lym-
phocytes expressing HLA-DR. Given these results and in view
of the relative cholesterol-lowering potency of rosuvastatin
compared with atorvastatin, we estimated that a sample size
of 20 participants would be adequate to observe potential inhib-
itory effects on inﬂammatory markers.
All statistical analyses were performed using IBM SPSS Sta-
tistics, version 20. Measurements at baseline and screening were
merged into 1 average value. Differences between patients and
controls were assessed by a Mann–Whitney U test for con-
tinuous variables and Fisher’s exact test for the dichotomous
variable race. A Spearman Rank test was used for analyzing
correlations.
Subsequently, the effect of rosuvastatin on markers of im-
mune activation in HIV-positive subjects was assessed. Both
baseline measurements (ie, week 0 and 12) were not taken
into account in the analyses due to the crossover design [21].
Continuous variables were primarily tested for normal dis-
tribution. Nonnormally distributed variables were natural log
transformed. Parameters that had a distinctly nonnormal distri-
bution were dichotomized for further analyses—based upon
upper and lower bounds known from common practice or
from 95% range of controls active in the trial. Thereafter, uni-
variate analyses without correcting for covariates were conduct-
ed: continuous outcome variables were analyzed by means of
linear mixed modeling (LMM) and dichotomous outcome var-
iables by means of generalized estimating equations (GEE).
Both LMM and GEE are constructive in analyses with correlat-
ed observations, ie, they are able to correct for the dependency
of the observations. Moreover, both analyses are able to include
incomplete cases due to the fact that missing outcomes are as-
sumed to be missing at random. Nevertheless, logistic multilevel
analysis (ie, LMM) results in an overestimation; therefore, GEE
analysis was used for dichotomous outcome variables because
its logistic analysis provides a more valid estimation, ie, smaller
regression coefﬁcients and standard errors due to its “popula-
tion average” approach compared with the “subject-speciﬁc”
approach in multilevel analysis. In LMM analyses, ﬁxed effects
for treatment-sequence (rosuvastatin-placebo vs placebo-
rosuvastatin) and treatment (rosuvastatin vs placebo) were
included as well as a random intercept for treatment on the
individual level. An unstructured covariance structure was
assumed. The possibility of a random slope was subsequently
investigated by means of the maximum likelihood ratio test
to achieve the most parsimonious model. In GEE analyses, an
exchangeable correlation structure was assumed [21].
Furthermore, multivariate analyses were conducted to investi-
gate confounding of covariates age (years) and race (Caucasian vs
other). Again, the unstructured and exchangeable working corre-
lation structures were used in LMM and GEE, respectively.
Finally, LMM was performed to assess the quality of life of
the participants during the trial measured by using the validated
MOS-HIV questionnaire and complaints list.
All analyses aforementioned were performed on an intention-
to-treat basis. Regression coefﬁcients (B) for normally distributed
continuous variables, geometric mean (GM) ratios for natural log-
transformed continuous variables, or odds ratios (OR) for dichot-
omous variables, and 95% conﬁdential intervals were obtained.
All P values of <.05 were considered to be statistically signiﬁcant.
RESULTS
Study Population
Of the 35 patients screened, 28 met the study criteria and were
randomized. During the ﬁrst cycle, 4 subjects in the placebo
group dropped out due to start of ART or for personal reasons.
During the second cycle, 2 subjects in the statin group dropped
out due to subjective side effects or lost to follow-up. In the pla-
cebo group, 2 subjects dropped out due to start of ART. Twenty
participants completed both cycles (Figure 1).
Table 1 shows the baseline characteristics. Patients were signif-
icantly older than controls (median 40 vs 27 years, P < .01). The
median duration of established HIV infection was 1.8 years, and
the median HIV-1 RNA was 30.750 copies/mL. Furthermore, at
baseline, patients had a signiﬁcantly lower CD4 count (480 vs
1080 cells/μL, P < .01), a higher CD8 count (1010 vs 530 cells/μL,
P < .01), and lower CD4/CD8 T-cell ratio (0.5 vs 1.9, P < .01).
Cholesterol levels were similar between both groups.
Immune Activation Markers Between Human Immunodeﬁciency Virus
Patients and Controls
Patients had higher median T-cell activation levels than controls
(eg, HLA-DR+CD38+ % of CD8+; 33.4 vs 5.6, P < .01) (Table 2).
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Only the CD38+ percentage of CD4+ cells was not signiﬁcantly
different. In addition, IL-18, sTLR2, and neopterin levels were
signiﬁcant higher in patients compared with controls (503.5 vs
322.5 pg/mL [P < .01], 3.4 vs 2.0 ng/mL [P < .01], and 19.5 vs
5.4 nmol/L [P < .01], respectively). The hsCRP levels were high-
er in patients, but this difference did not reach the level of stat-
istical signiﬁcance (1.3 vs 0.9 mg/L, P = .07). We did not observe
a difference in leukocyte count, D-dimer, IL-1Ra, IL-6, and
sTLR4 levels. In HIV-patients, age correlated negatively with
neopterin (R = −0.33, P < .01), sTLR2 (R = −0.25, P < .01),
HLA-DR+ % of CD8+ T cells (R = −0.26, P < .01), and HLA-
DR+CD38+ % of CD8+ T cells (R =−0.24, P < .01). No correla-
tion was found between age and IL-18 (R =−0.85, P = .31) and
other investigated markers of T-cell activation (data not shown).
Figure 1. Flow chart of study participants.
Table 1. Characteristics of Participants at Baselinea
Controls (n = 10) Patients (n = 28) P Value
Age, years 27 (24–33) 40 (34–47) <.01
Race, Caucasian 8 (80%) 23 (82%) .65
Lipid panel
Total cholesterol,
mmol/L
5.1 (3.3–6.1) 4.3 (3.9–5.1) .57
LDL, mmol/L 3.5 (1.5–3.8) 2.4 (2.1–3.1) .51
HIV parameters
Duration of
infection, years
− 1.8 (0.7–4.3) −
CD4 count, cells/µL 1.080 (580–1,230) 480 (450–680) <.01
CD8 count, cells/µL 530 (400–670) 1.010 (780–1,150) <.01
CD4/CD8 T-cell ratio 1.9 (1.2–2.7) 0.5 (0.4–0.9) <.01
HIV-1 RNA, copies/
mL
− 30.750 (13.350–91.375) −
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; LDL, low-
density lipoprotein.
a Data are presented as median (IQR) or as number (percentage). Differences between
patients and controls were assessed by a Mann–Whitney U test for continuous variables
and Fisher’s exact test for the dichotomous variable race (Caucasian vs other). Significant
results (P < .05) are presented in bold type.
Table 2. Markers of Immune Activation in Patients and Controlsa
Controls (n = 10) Patients (n = 28) P Value
T-cell activation
CD38+, % of CD4+ 56.3 (51.5–62.0) 60.4 (54.7–71.2) .11
HLA-DR+, % of CD4+ 5.2 (3.2–6.4) 13.7 (11.1–20.5) <.01
HLA-DR+CD38+,
% of CD4+
2.3 (1.6–3.8) 9.1 (6.6–14.8) <.01
CD38+, % of CD8+ 36.8 (29.5–46.5) 71.4 (58.2–82.5) <.01
HLA-DR+, % of CD8+ 8.7 (7.0–10.1) 39.0 (35.9–49.2) <.01
HLA-DR+CD38+,
% of CD8+
5.6 (4.1–7.2) 33.4 (29.9–40.8) <.01
Immune markers
Leukocytes, ×109/L 6.2 (4.4–7.0) 4.8 (4.4–7.0) .45
hsCRP, mg/L 0.9 (0.7–1.4) 1.3 (1.1–2.0) .07
D-dimer, mg/L 0.2 (0.2–0.4) 0.3 (0.2–0.6) .13
IL-1Ra, pg/mL 9.8 (9.8–9.8) 9.8 (9.8–9.8) .51
IL-6, pg/mL 2.4 (2.4–2.4) 2.4 (2.4–3.1) .22
IL-18, pg/mL 322.5 (159.0–390.0) 503.5 (382.0–859.5) <.01
sTLR2, ng/mL 2.0 (1.3–2.7) 3.4 (2.7–4.3) <.01
sTLR4, ng/mL 1.3 (1.3–1.3) 1.3 (1.3–1.3) .42
Neopterin, nmol/L 5.4 (2.9–6.9) 19.5 (11.7–27.8) <.01
Abbreviations: HLA, human leukocyte antigen; hsCRP, highly sensitive C-reactive protein; IL,
interleukin; IQR, interquartile range; LDL, low-density lipoprotein; sTLR, soluble Toll-like
receptor.
a Data are presented as median (IQR). Differences between patients and controls were
assessed by a Mann–Whitney U test. Significant results (P < .05) are presented in bold type.
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During rosuvastatin treatment, LDL cholesterol plasma level
decreased signiﬁcantly compared with placebo treatment
(B = −0.94 mmol/L, P < .01) (Table 3). The CD4 counts in-
creased during statin treatment, but this did not reach the
level of signiﬁcance (B = 36 cells/μL, P = .08). CD4/CD8 T-cell
ratio showed a small but signiﬁcant increase (GM ratio = 1.11,
P = .02). No change in HIV-1 RNA (GM ratio = 0.97, P = .77)
nor on CD8 count (GM ratio = 0.95, P = .24) was found. More-
over, we did not observe an effect on T-cell activation markers
(eg, HLA-DR+CD38+ % of CD8+; GM ratio = 1.00, P = .95).
Likewise, no treatment effect was found on levels of leuko-
cytes (GM ratio = 1.04, P = .39), hsCRP (GM ratio = 0.02,
P = .69), D-dimer (OR = 0.80, P = .61), sTLR2 (GM ratio = 0.89,
P = .25), nor on neopterin (B = 0.7 nmol/L, P = .75).
During statin use, ALT and AST levels increased signiﬁcantly
(GM ratio = 1.49, P < .01 and GM ratio = 1.26, P < .01, respective-
ly). Creatine kinase and creatinine did not show any change (GM
ratio = 1.19, P = .29 and GM ratio = 1.01, P = .37, respectively).
Quality of Life During the Trial
During rosuvastatin treatment, more ﬂu-like symptoms were re-
ported (−16 of 100 point, P < .01) (Table 4). There was no sig-
niﬁcant difference in other complaints because the MOS-HIV
questionnaire did not reveal any signiﬁcant differences between
statin and placebo treatment.
DISCUSSION
In this exploratory study in ART-naive HIV-patients, we inves-
tigated the effect of 20 mg of rosuvastatin on soluble markers of
immune activation and on T-cell activation. As expected, the
Table 3. The Effect of Rosuvastatin on Markers of Immune Activation in HIV-Infected Patientsa
Univariate Analysis Multivariate Analysis
B*/GM ratio/OR** (95% CI) P Value B*/GM ratio/OR** (95% CI) P Value
LDL, mmol/L* −0.94 (−1.17 to −.71) <.01 −0.91 (−1.14 to −.68) <.01
HIV variables
HIV-1 RNA, copies/mL 0.97 (.78–1.20) .75 0.97 (.78–1.21) .77
CD3+ count, cells/µL 0.99 (.92–1.07) .86 0.99 (.87–0.99) .82
CD4+ count, cells/µL* 36 (−4 to −75) .07 36 (−4 to 77) .08
CD8+ count, cells/µL 0.95 (.87 to 1.04) .26 0.95 (.67–1.04) .24
CD4/CD8 ratio 1.10 (1.00–1.21) .04 1.11 (1.02–1.21) .02
T-cell activation
CD38+, % of CD4+* −0.82 (−3.59 to 1.96) .56 −0.89 (−3.67 to 1.90) .63
HLA-DR+, % of CD4+ 1.01 (.91–1.13) .80 1.02 (.91–1.13) .74
HLA-DR+CD38+, % of CD4+ 1.02 (.90–1.16) .74 1.02 (.90–1.16) .90
CD38+, % of CD8+* −1.63 (−4.41 to 1.16) .25 −1.66 (−4.45 to 1.13) .24
HLA-DR+, % of CD8+* 1.16 (−2.59 to 4.91) .52 1.24 (−2.49 to 4.96) .50
HLA-DR+CD38+, % of CD8+ 1.00 (.90–1.10) .95 1.00 (.90–1.10) .95
Immune markers
Leukocytes, ×109/L 1.03 (.94–1.14) .49 1.04 (.94–1.15) .39
hsCRP, (ref. = <10 mg/L)** 0.52 (.03–10.06) .67 0.54 (.02–11.95) .69
D-dimer, (ref. = <0.5 mg/L)** 0.75 (.41–1.38) .36 0.80 (.64–1.86) .61
IL-1ra, (ref. = <21.15 pg/mL)** 1.36 (.70–2.62) .36 1.33 (.69–2.56) .40
IL-6, (ref. = <5.4 pg/mL)** 2.43 (.39–15.23) .34 n.v. –
IL-18, pg/mL 1.10 (.87–1.39) .43 1.09 (.99–1.38) .47
sTLR2, ng/mL 0.89 (.87–1.39) .23 0.89 (.73–1.09) .25
sTLR4, (ref. = <1.463 ng/mL)** n.v. – n.v. –
Neopterin, nmol/L* 0.99 (−3.23 to 5.21) .63 0.66 (−3.64 to 4.95) .75
Other parameters
CK 1.19 (.85–1.66) .30 1.19 (.85–1.67) .29
Creatinine 1.01 (.98–1.05) .36 1.01 (.98–1.05) .37
ALT 1.51 (1.28–1.76) <.01 1.49 (1.27–1.75) <.01
AST 1.28 (1.14–1.41) <.01 1.26 (1.13–1.41) <.01
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; CK, creatine kinase; GEE, generalized estimating equations; GM, geometric mean; HIV,
human immunodeficiency virus; HLA, human leukocyte antigen; hsCRP, highly sensitive C-reactive protein; IL, interleukin; LMM, linear mixed modeling; n.v., not enough variability to be
analyzed; OR, odds ratio; ref., reference; sTLR, soluble Toll-like receptor.
a References for dichotomous variables were set on clinical reference range or 95% range of controls and are denoted between brackets. Significant results (P < .05) are presented in bold type.
* Effect measures for continuous variables are presented as regression coefficients (B) (95% CI) when normally distributed or as GM ratio (95% CI) when natural log transformed (both analyzed
by LMM).
** Effect measures for dichotomous outcome variables are presented as OR (95% CI) (analyzed by GEE). Multivariate analyses were adjusted for age and race.
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patients infected with HIV displayed substantially increased
T-cell activation compared with healthy controls. In contrast
to other studies, we did not ﬁnd increased concentrations of
IL-6 or hsCRP (for the latter, the difference just failing statistical
signiﬁcance). This discrepancy may be due to the small sample
size. However, other markers of monocyte/macrophage activa-
tion were increased in patients compared with controls, among
which were neopterin, IL-18, and sTLR-2.
Increased concentrations of neopterin have been described
before in patients infected with HIV and were associated with
other markers of monocyte activation in these patients [22].
The increased concentrations of IL-18 in our patients is in
accordance with the ﬁndings of other studies, in which IL-18
concentrations correlated positively with HIV viral load and
negatively with CD4 cell counts [23, 24]. We are the ﬁrst to
describe elevated concentrations of sTLR-2 in patients infected
with HIV. Soluble TLR-2 correlates positively with other in-
ﬂammatory markers such as tumor necrosis factor-α, IL-6,
and IL-1Ra [25]. Taken together, these ﬁndings conﬁrm that
our group of ART-naive HIV-patients showed substantial
immune activation.
We did not ﬁnd an effect of rosuvastatin on any of the soluble
markers of inﬂammation measured. Very few other studies have
investigated the effect of statins on soluble markers of monocyte
activation or inﬂammation in patients infected with HIV. In an
uncontrolled study, a reduction in CRP concentration was ob-
served after 45 days of pravastatin or rosuvastatin in patients
treated with ART [26]. Eckard et al [27], investigating patients
treated with ART, did not ﬁnd an effect on hsCRP concentra-
tions after 24 weeks of 10 mg rosuvastatin, but the same group
reported a decrease of soluble CD14 [28].These effects seemed to
be more pronounced after 48 weeks of rosuvastatin [15]. Thus,
the lack of an effect on soluble markers of inﬂammation in our
study may be due to the relatively short duration of treatment.
Although we found a signiﬁcant activation of CD8 cells in
our patients at baseline, we did not observe a reduction of T-
cell activation after 8 weeks of rosuvastatin treatment. However,
we did observe a small but signiﬁcant increase in CD4/CD8
ratio, which may be regarded as an indirect sign of decreased
T-cell activation. Our study design was similar to the study by
Ganesan et al [14], who treated ART-naive HIV-patients with 8
weeks of 80 mg atorvastatin and found signiﬁcant reductions in
circulating proportions of CD4+HLA-DR+, CD8+ HLA-DR+,
and CD8+HLA-DR+CD38+ T cells. They did not report on
changes of CD4/CD8 ratio. The differences between our ﬁnd-
ings and the study of Ganesan et al [14] remain speculative. Pos-
sible explanations may include the fact that rosuvastatin is a
hydrophilic statin, whereas atorvastatin is lipophilic. Direct in-
hibition of T-cell activation in vitro has been reported with ator-
vastatin [29]. In vivo, the effects of statins on T-cell activation in
non-HIV-patients have shown divergent results [30–32]. Of
course, we cannot exclude the possibility that statins have
only marginal effects on inﬂammatory markers in patients in-
fected with HIV, and that small differences between studies are
merely the result of biological variation between the patients in
the various studies.
Rosuvastatin treatment resulted in well known side effects,
such as ﬂu-like symptoms and elevation of liver enzymes.
Only 1 patient had to discontinue the study due to side effects.
Our study may have been underpowered due to a high number
of patient withdrawal of an already small sample size. Therefore,
we consider our study as being exploratory. In this respect, it is
noteworthy that a substantial number of subjects withdrew
from the study during the placebo phase because their CD4
cell count dropped and they had to start ART. As mentioned be-
fore, although the signiﬁcant decline in LDL cholesterol suggests
adequate rosuvastatin intake, 8 weeks may be too short a period
for a detectable effect on immune activation markers. Future re-
search may investigate the effects of statins on markers of inﬂam-
mation for a longer time period and in a larger study population.
Possible differential effects of hydrophilic versus lipophilic statins
may also be of interest in future studies. The fact that we chose to
study ART-naive HIV-infected subjects to exclude the effect of
ART on immune activation has its limitations. In future studies,
an additional effect of statins on immune activation in ART-
treated patients may be harder to detect.
CONCLUSIONS
In conclusion, this small group of treatment-naive HIV-infected
patients had higher levels of T-cell activation markers and high-
er circulating neopterin, IL-18, and sTLR2 levels compared with
controls. Eight weeks of rosuvastatin had a small but signiﬁcant
positive effect on CD4/CD8 T-cell ratio, but no inﬂuence on
other markers of T-cell activation and innate immunity was
identiﬁed.
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